TheraRadar
← Back
Data updated: Jun 28, 2026

MDGH

Pharma
Pharmaceuticals

MDGH is a pharmaceutical company with 1 FDA-approved products.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

FDA Novel Drug Designations

(2018)
1 Novel 1 Orphan 1 Priority Review
See 1 novel approval →
2018 MOXIDECTIN Orphan · Priority Review

MDGH's Key Drugs

MDGH's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MDGH's Recent FDA Approvals

New NDA/BLA approvals for MDGH over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MDGH's Therapeutic Areas

Disease areas where MDGH has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

MDGH Pipeline Snapshot

Active clinical trials for MDGH across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling